secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2026-07-08T20:05:33+00:00
Accession:  0001193125-26-298526
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

GSK terminates collaboration with Alector after Phase 3/2 failures; loan repaid
-------------------------------------------------------------------------------

- GSK provided notice terminating the collaboration agreement for latozinemab and nivisnebart, effective Jan 2, 2027.
- Phase 3 INFRONT-3 trial of latozinemab in FTD-GRN missed co-primary endpoint (Oct 2025); Phase 2 PROGRESS-AD of nivisnebart discontinued (Apr 2026).
- Alector repaid $10.4M principal plus interest and fees to Hercules Capital, terminating the loan agreement on July 8, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000119312526298526/0001193125-26-298526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000119312526298526/alec-20260706.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-298526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer